Y-mAbs Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Y-mAbs Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 30% to $84,819,000. The net income raised on -$21,427,000 and profit margin reached -25%. Total operating expenses were $99,075,000.
Profit Margin
| 2016 | 0 | -17.05M | |
|---|---|---|---|
| 2017 | 0 | -19.16M | |
| 2018 | 0 | -43.27M | |
| 2019 | 0 | -78.88M | |
| 2020 | 20.75M | -118.34M | -570.33% |
| 2021 | 34.89M | -56.34M | -161.46% |
| 2022 | 65.26M | -96.32M | -147.59% |
| 2023 | 84.81M | -21.42M | -25.26% |
YMAB Income Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue | 84.81M | 65.26M | 34.89M | 20.75M | 0 | 0 | 0 | 0 |
Cost of revenue | 11.41M | 7.56M | 2.51M | 2.20M | 166K | 0 | 0 | 0 |
Gross profit | 73.40M | 57.7M | 32.38M | 18.54M | -166K | 0 | 0 | 0 |
Operating exp. | ||||||||
Research and development | 54.21M | 91.57M | 93.24M | 93.69M | 63.49M | 34.26M | 14.30M | 13.85M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 99.07M | 152.51M | 147.81M | 138.48M | 83.00M | 43.23M | 19.24M | 17.03M |
Operating income | -25.67M | -94.81M | -115.43M | -119.93M | -83.00M | -43.23M | -19.24M | -17.03M |
Other income (expenses), net | 4.80M | -757K | 60.15M | 598K | 1.97M | -44K | 83K | -18K |
Income before tax | -20.86M | -95.56M | -55.27M | -119.33M | -81.02M | -43.27M | -19.16M | -17.05M |
Income tax expense | 561K | 757K | 1.07M | -994K | -2.14M | -44K | -19.24M | 0 |
Net income | -21.42M | -96.32M | -56.34M | -118.34M | -78.88M | -43.27M | -19.16M | -17.05M |
Earnings per share | ||||||||
Basic EPS | -0.49 | -2.2 | -1.3 | -2.95 | -2.24 | -1.5 | -0.58 | -0.51 |
Diluted EPS | -0.49 | -2.2 | -1.3 | -2.95 | -2.24 | -1.5 | -0.58 | -0.51 |
| Data source | Data source | Data source | Data source | Data source | Data source |